Elango Subramoniapillai

Authors' reply to ‘Comments on dose‐dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy’

Ashleigh Scott, Ada Lo, Ying Xia, Kate Thompson et autres

Individual participant imaging data are not publicly available due to participant privacy requirements, and hence summary data are published in full in the supplementary appendix. Deidentified imaging datasets are available from the corresponding author on reasonable request.

au (code pays fourni par la source)

Dose‐dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy

Ashleigh Scott, Ada Lo, Ying Xia, Kate Thompson et autres

Summary ‘Chemobrain’ language symptoms are commonly reported by adults receiving intensive chemotherapy for acute myeloid leukaemia (AML), but real‐time detection eludes clinical imaging modalities. We performed a prospective, observational, longitudinal cohort study employing serial comprehensive neurocognitive assessment and brain functional MRI (fMRI) …

au (code pays fourni par la source)

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

Real World Outcomes of Ruxolitinib Treatment of Steroid Refractory/Dependent Acute Graft Versus Host Disease

Becky Leung, Jason Butler, Cameron Curley, Andrea Henden et autres

Aim: Steroid-refractory and/or dependent acute graft versus host disease (SR/SD-aGVHD) is a life-threatening complication following allogeneic haematopoietic stem cell transplantation (HSCT). The REACH-2 study established ruxolitinib as standard of care compared to historical salvage options, however patients with lower gastrointestinal (GI) involvement …

au (code pays fourni par la source)

Allogeneic Haematopoietic Stem Cell Transplantation Is Safe and Effective for Myeloid Neoplasms with Germline DDX41 Mutation

Ricky Nelles, Jason Butler, Cameron Curley, Andrea Henden et autres

Aim: Germline DDX41 mutations define specific myeloid neoplasm subtypes including AML and MDS. Whilst DDX41-mutated patients often undergo allogeneic haematopoietic stem cell transplant (HSCT), recent retrospective analyses have reported higher severe acute and chronic graft vs host disease (GVHD)1 and inferior survival2 …

au (code pays fourni par la source)

Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years

Rajiv Khanna, George Ambalathingal, Nada Hamad, Joe Sasadeusz et autres

au, us, kr, nz, in, gb (code pays fourni par la source)

Granulocyte transfusion supportive care for prolonged cytopenias post CD19 CAR T cell therapy

Nilu Perera, Shoma Baidya, N Weber, Kari Mudie et autres

Table S1. Specifications regarding granulocyte transfusions infused. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the …

au (code pays fourni par la source)

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

Conclusions LJE & ZM and EMW & SJS contributed equally Patients undergoing treatment for hematologic malignancies continue to have a high burden of clinically significant bleeding (WHO grade 2 or above) despite receiving prophylactic platelet transfusions (43% in TOPPS trial, NEJM 2013). …

gb, au, us, kr (code pays fourni par la source)

Quantifying skin cancer risk following allogeneic haematopoietic cell transplant in Queensland, Australia

Philip Wong, David C. Whiteman, Catherine M. Olsen, Yin Yuan et autres

au (code pays fourni par la source)

High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell transplantation

Yin Yuan, Philip Wong, Jason Butler, Andrea Henden et autres

au (code pays fourni par la source)

Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance

Stephen Boyle, Joshua W.D. Tobin, Jacinta Perram, Nada Hamad et autres

There are limited data on post-transplant lymphoproliferative disorder (PTLD) in the era of positron emission tomography (PET) and rituximab (R). Furthermore, there is limited data on the risk of graft rejection with modern practices in reduction in immunosuppression (RIS). We studied 91 …

au (code pays fourni par la source)

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Glen Kennedy, Siok‐Keen Tey, Luke Buizen, Antiopi Varelias et autres

We determined the efficacy of tocilizumab (TCZ) in preventing grade 2-4 acute graft-versus-host disease (aGVHD) in patients with acute leukemia or myelodysplasia undergoing matched sibling donor (MSD) or volunteer unrelated donor (VUD) allogeneic stem cell transplantation after myeloablative or reduced-intensity conditioning across …

au (code pays fourni par la source)